{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:24:51Z","timestamp":1794327891342,"version":"4.9.0"},"reference-count":36,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,3,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>In patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated the efficacy and safety of BV + Len + R versus placebo + Len + R in patients with R\/R DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing BV + Len + R with placebo + Len + R in patients with R\/R DLBCL. Patients received BV or placebo once every 3 weeks, Len once daily, and R once every 3 weeks. The primary end point was overall survival (OS), and secondary end points included investigator-assessed progression-free survival (PFS) and objective response rate (ORR). A prespecified interim analysis was performed after 134 OS events, with two-sided\n                      <jats:italic>P<\/jats:italic>\n                      = .0232 as the efficacy boundary.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Patients (N = 230) were randomly assigned to receive BV + Len + R (n = 112) or placebo + Len + R (n = 118). Two patients in the placebo arm did not receive treatment. With a median follow-up of 16.4 months, the median OS was 13.8 months with BV + Len + R versus 8.5 months with placebo + Len + R (hazard ratio, 0.63 [95% CI, 0.45 to 0.89]; two-sided\n                      <jats:italic>P<\/jats:italic>\n                      = .009). The median PFS was 4.2 months with BV + Len + R versus 2.6 months with placebo + Len + R (hazard ratio, 0.53 [95% CI, 0.38 to 0.73]; two-sided\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .001). The ORR was 64% ([95% CI, 55 to 73]; two-sided\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .001) with BV + Len + R and 42% (95% CI, 33 to 51) with placebo + Len + R; complete response rates were 40% and 19%, respectively. Treatment-emergent adverse events (AEs) occurred in 97% of patients in both arms. In both arms, the most common treatment-emergent AEs were neutropenia, thrombocytopenia, diarrhea, and anemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>BV + Len + R demonstrated a statistically significant survival benefit with a manageable safety profile in heavily pretreated patients with R\/R DLBCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-24-02242","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T15:59:28Z","timestamp":1736265568000},"page":"1061-1072","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":55,"title":["Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct04404283","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":true,"given":"Nancy L.","family":"Bartlett","sequence":"first","affiliation":[{"name":"Division of Oncology, Washington University School of Medicine, Siteman Cancer Center, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Hahn","sequence":"additional","affiliation":[{"name":"Haematology Unit, Royal Adelaide Hospital, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-0466","authenticated-orcid":true,"given":"Won-Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[{"name":"H\u00f4pital Maisonneuve-Rosemont, Institut Universitaire d\u2019H\u00e9matologie-Oncologie et de Th\u00e9rapie Cellulaire, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5589-7570","authenticated-orcid":true,"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Le Mans, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8229-1208","authenticated-orcid":true,"given":"Juan-Miguel","family":"Bergua","sequence":"additional","affiliation":[{"name":"Hospital San Pedro de Alcantara, C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie Clinique et Therapie Cellulaire, CHU Haut-Leveque, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Forward","sequence":"additional","affiliation":[{"name":"Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6768-7175","authenticated-orcid":true,"given":"Fontanet","family":"Bijou","sequence":"additional","affiliation":[{"name":"Centre de Lutte Contre le Cancer (CLCC)\u2014Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7750-2733","authenticated-orcid":true,"given":"David","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9487-8345","authenticated-orcid":true,"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[{"name":"UVA Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Ghesquieres","sequence":"additional","affiliation":[{"name":"Hematology Department, H\u00f4pital Lyon Sud\u2014HCL, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":true,"given":"Grzegorz","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-156X","authenticated-orcid":true,"given":"Christopher A.","family":"Yasenchak","sequence":"additional","affiliation":[{"name":"Willamette Valley Cancer Institute and Research Center\/US Oncology Research, Eugene, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Patterson","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ho","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Rustia","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Jie","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-A","family":"Kim","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24086"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S193951"},{"key":"e_1_3_11_10_2","volume-title":"Adcetris (Brentuximab Vedotin) Highlights of Prescribing Information","author":"US Food and Drug Administration","year":"2023","unstructured":"US Food and Drug Administration: Adcetris (Brentuximab Vedotin) Highlights of Prescribing Information. Pfizer, 2023"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598763"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2818"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.02.001"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011894"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847576.88118.d6"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_11_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02786"},{"key":"e_1_3_11_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7525"},{"key":"e_1_3_11_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"e_1_3_11_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_3_11_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00345-9"},{"key":"e_1_3_11_29_2","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi PF","year":"2024","unstructured":"Caimi PF, Ai WZ, Alderuccio JP, et al: Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica 109:1184-1193, 2024","journal-title":"Haematologica"},{"key":"e_1_3_11_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"e_1_3_11_31_2","volume-title":"Zynlonta (Loncastuximab Tesirine) Highlights of Prescribing Information","author":"US Food and Drug Administration","year":"2023","unstructured":"US Food and Drug Administration: Zynlonta (Loncastuximab Tesirine) Highlights of Prescribing Information. ADC Therapeutics, 2023"},{"key":"e_1_3_11_32_2","volume-title":"Polivy (Polatuzumab Vedotin) Highlights of Prescribing Information","author":"US Food and Drug Administration","year":"2024","unstructured":"US Food and Drug Administration: Polivy (Polatuzumab Vedotin) Highlights of Prescribing Information. Genentech, 2024"},{"key":"e_1_3_11_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"e_1_3_11_34_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.275958"},{"key":"e_1_3_11_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac137"},{"key":"e_1_3_11_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2069"},{"key":"e_1_3_11_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-24-02242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T18:00:56Z","timestamp":1741975256000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-24-02242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,3,20]]}},"alternative-id":["10.1200\/JCO-24-02242"],"URL":"https:\/\/doi.org\/10.1200\/jco-24-02242","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"2024-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}